News

The Texas Medical Center (TMC) Venture Fund, an early-stage healthcare investor, today announced the acquisition of its portfolio company, CrossBridge Bio, Inc., by Eli Lilly and Company for $300 million. The transaction reflects TMC Venture Fund’s role as lead investor in CrossBridge Bio and its ability to advance early-stage companies toward successful exit.

CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs) today announced a definitive agreement to be acquired by Eli Lilly and Company (“Lilly”).

For medical device startups, funding is never far from mind. A device doesn’t make the leap from a design on paper to a patient’s bedside without the right financial backing.

Surf Therapeutics, a clinical-stage neuro-immunomodulation company developing non-invasive ultrasound therapy for chronic inflammatory diseases, is announcing the start of an Early Feasibility Study evaluating its investigational ultrasound device in people living with rheumatoid arthritis.

Prana Surgical, a Houston-based medical device company, today announced the completion of the first five clinical procedures using the Prana System™ as part of its early feasibility study in Australia. The Prana System™ has been developed to enable image-guided, minimally invasive surgery, conserving healthy tissue and driving personalized treatment plans in a range of conditions,

Cadwell, a global leader in neurodiagnostic and monitoring solutions, and Medical Informatics Corp (MIC), creators of the Sickbay Clinical Platform, today announced a strategic partnership that aims to bring a new standard of integrated data and monitoring to hospitals. As part of the agreement, Cadwell systems will be the first neurodiagnostic product integrated with Sickbay’s